Background. A randomized, double-blind study was conducted to evaluate the
pharmacokinetics of ganciclovir following oral administration of ganciclovir or valganciclovir …

Seventeen recipients of renal transplants were treated with ganciclovir for life-or sight-
threatening cytomegalovirus (CMV) infection. Twelve patients had pneumonia (one with …

Infection with human cytomegalovirus (CMV) is an important cause of morbidity and mortality
in kidney transplant recipients. CMV disease is diagnosed based on the detection of viral …

Ganciclovir is a nucleoside guanosine analogue which incorporates ganciclovir
triphosphate (the active moiety) into DNA during elongation, thereby inhibiting viral …

The efficacy and safety of valganciclovir (VGCV) for cytomegalovirus (CMV) prophylaxis in
liver transplant recipients has not been established. We retrospectively compared the …

Recurrent CMV disease has been reported to occur in 6% to 59% of solid-organ transplant
recipients. The consequences of recurrent CMV disease after the treatment of the first CMV …

Antiviral compounds including ganciclovir, foscarnet, and cidofovir are routinely used in the
treatment of cytomegalovirus (CMV) infection and disease; however, these agents have a …

Background. Organ transplant recipients who are seropositive for cytomegalovirus (CMV)
and who are treated with antilymphocyte antibody (ALA) therapy have a high rate of …

The efficacy and safety of oral valganciclovir was compared to ganciclovir iv in pre-emptive
treatment of cytomegalovirus (CMV) in T-cell-depleted allogeneic stem cell transplant (allo …

Cytomegalovirus (CMV) continues to be a cause of substantial morbidity and death after
solid-organ transplantation. There are 3 major consequences of CMV infection: CMV …